Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Non Operating Investment Income (2023)

Spyre Therapeutics (SYRE) has disclosed Non Operating Investment Income for 2 consecutive years, with -$800000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Non Operating Investment Income rose 96.06% year-over-year to -$800000.0, compared with a TTM value of -$40.7 million through Dec 2024, up 60.81%, and an annual FY2024 reading of -$20.4 million, down 7.61% over the prior year.
  • Non Operating Investment Income was -$800000.0 for Q4 2024 at Spyre Therapeutics, up from -$19.6 million in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at -$800000.0 in Q4 2024 and bottomed at -$58.2 million in Q2 2023.